-+ 0.00%
-+ 0.00%
-+ 0.00%
Revelation Biosciences selects Avance Clinical as CRO for Phase 2/3 AKI study of Gemini
Share
Listen to the news
Revelation Biosciences selects Avance Clinical as CRO for Phase 2/3 AKI study of Gemini
  • Revelation Biosciences selected Avance Clinical as contract research organization for its Phase 2/3 adaptive-design TITAN study of Gemini in acute kidney injury.
  • The study remains on track to start later this year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608190900BIZWIRE_USPR_____20260819_BW546599) on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending